[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500300":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":31,"responsibleParty":53,"collaborators":19,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":19,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":19,"enrollmentInfo":64,"targetDuration":19,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"University Hospital Ostrava","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Catheter ablation and\u002For electrical cardioversion","EXPERIMENTAL","Study subjects indicated for catheter ablation and\u002For electrical cardioversion will be enrolled in this study arm.",[13],"Procedure: Catheter ablation and\u002For electrical cardioversion",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","Catheter ablation and\u002For electrical cardio version are procedures intended to treat atrial fibrillation.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Jiří Plášek, MD,PhD,FESC","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},"Jiří Hynčica","CONTACT","0042059737","2587","jiri.hyncica@fno.cz",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":19,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Ostrava","Moravian-Silesian Region","70852","Czechia",{"type":39,"coordinates":40},"Point",[41,42],18.28204,49.83465,{"lat":42,"lon":41},[45,47,48,51],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":46},"eticka.komise@fno.cz",{"name":22,"role":23,"phone":19,"phoneExt":19,"email":19},{"name":49,"role":50,"phone":19,"phoneExt":19,"email":19},"Jan Václavík, prof.,MD,PhD,FESC","SUB_INVESTIGATOR",{"name":52,"role":50,"phone":19,"phoneExt":19,"email":19},"David Stejskal, prof.,MD,PhD,EurChem",{"type":54,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100500300","the-safe-prospective-registry-100500300",false,"NCT05794464","The SAFE Prospective Registry","Secretoneurin as a Biomarker of Atrial Fibrillation rEcurrence After Catheter Ablation\u002FElectrical Cardioversion","Inclusion Criteria:\n\n* Atrial fibrillation (Afib); (paroxysmal, persistent)\n* Patients indicated for catheter ablation and\u002For electrical cardioversion\n* Signed informed consent\n\nExclusion Criteria:\n\n* Longstanding or permanent atrial fibrillation\n* Severe mitral regurgitation\n* Heart failure with a permanently reduced ejection fraction\n* Cerebral ischaemic stroke in \\\u003C 3 months\n* Severe kidney injury\n* Severe renal insufficiency\n* Hepatic insufficiency limiting biomarker sampling\n* Myocardial infarction \\\u003C 3 months","ALL","18 Years",{"count":65,"type":66},60,"ESTIMATED","INTERVENTIONAL",[69],"NA","Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.",[72],"Atrial Fibrillation, Paroxysmal or Persistent",[74,75,76,77],"atrial fibrillation","secretoneurin","catheter ablation","electrical cardio version","2023-09-06",{"date":80,"type":81},"2023-09-07","ACTUAL",{"date":83,"type":81},"2023-05-01",{"date":85,"type":66},"2026-08",{"name":5,"class":6},1]